Search clinical trials for: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)

Total 30 results

Bayer

Completed

Treatment of Vasomotor Symptoms in Korean Post Menopausal Women

Vasomotor Symptoms

Korea, Republic of
Bayer

Completed

Angeliq Regulatory Post Marketing Surveillance (Angeliq rPMS)

Osteoporosis, Postmenopausal | Postmenopausal Period

Korea, Republic of
Bayer

Completed

Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women

Hypertension | Postmenopause
Bayer

Completed

Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.

Vasomotor Symptoms

China
Bayer

Completed

Efficacy and Tolerability of Angeliq in Thai Women

Postmenopause
Bayer

Completed

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

Hypertension | Postmenopause | Pre-Hypertension

United States
Bayer

Completed

A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles

Contraception

Germany
Bayer

Completed

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

Vasomotor Symptoms | Hot Flashes

United States
Brigham and Women's Hospital
Bayer

Completed

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

Cardiovascular Diseases

United States
Bayer

Completed

Yasmin Post Marketing Surveillance

Contraception

Korea, Republic of
Bayer

Completed

LCS16 vs. COC User Satisfaction and Tolerability Study

Contraception

Russian Federation
NewAmsterdam Pharma
Novum

Recruiting

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Healthy Volunteers

United States
Teva Pharmaceuticals USA

Completed

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

Healthy

United States
Bio-innova Co., Ltd

Not yet recruiting

Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®

Healthy Subjects
Bayer

Completed

Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)

Contraception

Saudi Arabia, Jordan, Lebanon, Bahrain, Kuwait, Oman, Qatar, Hungary, Albania, Egypt, Kenya, Macedonia, The Former Yugoslav Republic of, United Arab Emirates
AGUNCO Obstetrics and Gynecology Centre

Completed

Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance

Polycystic Ovary Syndrome | PCOS

Italy
Bio-innova Co., Ltd

Recruiting

Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®

Healthy Subjects

Thailand
Catholic University of the Sacred Heart

Completed

Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.

Polycystic Ovary Syndrome | Estro-progestin Drugs

Italy
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females

Contraception
Denusa Wiltgen
Hospital de Clinicas de Porto Alegre; Coordenação de Aperfeiçoamento de Pessoal... and other collaborators

Completed

Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women

Postmenopause

Brazil
NewGiza University
Ain Shams University

Not yet recruiting

The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study

Observational Study
Bayer

Completed

Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D

Contraceptives, Oral

Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

Oral Contraceptive | Follicle Development | Ovarian Follicle | Follicle Count | Follicle Size

United States
Bayer

Completed

Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium

Contraception | Ovulation Inhibition

Germany
Adana Numune Training and Research Hospital

Completed

Treatment Choice in Primary Dysmenorrhea

Primary Dysmenorrhea
Bayer

Completed

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Metrorrhagia

United States, Canada
Bayer

Completed

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Metrorrhagia

Sweden, Germany, Poland, Finland, Australia, Czech Republic, Hungary, Netherlands, Ukraine, United Kingdom
Bayer

Completed

Effect on Primary Dysmenorrhea

Primary Dysmenorrhea

Italy, Chile, United States, Philippines, Canada, Germany
Bayer

Completed

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

Contraception

United States, Canada

3

Subscribe